Suppressed CD31 Expression in Sarcoma-180 Tumors after Injection with Toxoplasma gondii Lysate Antigen in BALB/c Mice.
10.3347/kjp.2010.48.2.171
- Author:
Kyoung Ho PYO
1
;
Bong Kwang JUNG
;
Jong Yil CHAI
;
Eun Hee SHIN
Author Information
1. Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, and Institute of Endemic Diseases, Seoul National University Medical Research Center, Seoul 110-799, Korea.
- Publication Type:Brief Communication ; Research Support, Non-U.S. Gov't
- Keywords:
Toxoplasma gondii;
lysate antigen;
CD31;
sarcoma-180;
anti-tumorigenic effect
- From:The Korean Journal of Parasitology
2010;48(2):171-174
- CountryRepublic of Korea
- Language:English
-
Abstract:
The anti-tumorigenic effects of Toxoplasma gondii (RH) antigens were studied in a murine sarcoma-180 tumor model. To determine the anti-tumor effects, the reduction in tumor size and expression of CD31 (an angiogenesis marker in the tumor tissue) were examined after injection of BALB/c mice with T. gondii lysate antigen (TLA) or formalin-fixed, proliferation-inhibited, T. gondii tachyzoites. Tumors were successfully produced by an intradermal injection of sarcoma-180 cells with plain Matrigel in the mid-backs of mice. After injection with TLA or formalin-fixed T. gondii tachyzoites, the increase in tumor size and weight nearly stopped while tumor growth continued in control mice that were injected with PBS. CD31 expression in TLA-treated or formalin-fixed T. gondii-injected mice was lower than the control mice. Accordingly, the present study shows that the treatment of mice with formalin-fixed T. gondii or TLA in the murine sarcoma-180 tumor model results in a decrease of both tumor size and CD31 expression.
